Aphios
Corporation Announces Launch of SuperCool Gingerol for Calming
Stomachs and Healthy Digestion
November
17, 2004
- Aphios Corporation today announced the launch of its SuperCool™
Gingerol dietary supplement product for calming stomachs
and healthy digestion.
SuperCool™
Gingerol is an advanced formulation of an enhanced gingerols
and shogaols fraction of Ginger or Zingiber, the dried rhizome
of Zingiber officinale Roscoe (Family Zingiberaceae) known
commercially as Jamaica ginger, African ginger and China
ginger. Aphios’ SuperCool™ Gingerol product is
standardized against gingerols and shogaols. Ginger has
become widely accepted as a treatment for nausea. Ginger
is listed on the FDA’s GRAS (generally regarded as
safe) list as a food.
SuperCool™
Gingerol’s sister product Zindol™ is currently
in a multi-center Phase II/III, dose-finding, placebo-controlled
clinical trial for nausea in cancer patients undergoing
chemotherapy. Nausea and emesis (an act or instance of vomiting)
are not diseases but symptoms associated with several conditions
including flatulence, motion sickness, surgery, pregnancy
and cancer chemotherapy. Trevor Castor, CEO, Aphios states:
“There is still a great deal of room for improvement
in the control of nausea and emesis associated with cancer
chemotherapy. A desirable attribute in any substitute or
additional anti-emetic medication would be the absence of
clinically significant adverse effects.”
Environmental
friendly and nontoxic SuperFluids™ carbon
dioxide technologies (U.S. Patents) were used to discover
and are being used to manufacture the active ingredients
of SuperCool™ Gingerol. The product is formulated and
encapsulated by Pfizer, Inc. in accordance with cGMP (current
Good Manufacturing Practices) of the United States Food
and Drug Administration (FDA).
SuperCool™
Gingerol has not been evaluated by the FDA and is not intended
to diagnose, treat, cure or prevent disease. As with any
dietary supplement, consumers should consult their physician
before taking this product. Research leading to the development
of SuperCool™ Gingerol was funded, in part, by the
National Cancer Institute (NCI), National Institutes of
Health (NIH).
Aphios
Corporation (www.aphios.com)
is developing enabling SuperFluids™ technology
platforms for improving the discovery, manufacturing, pathogenic
safety and delivery of therapeutic drugs and utilizing these
platforms to develop enhanced therapeutics for health maintenance
and the treatment of human diseases with a focus on infectious
diseases, oncology and quality-of-life medicines.
For
more information on SuperCool™ Gingerol, please visit
www.supercoolhealth.com.
